Skip to content

Study · Non-randomized trial · n = 9 · 1997

6 results

Treatment of radiation-induced growth hormone deficiency with growth hormone-releasing hormone.

Ogilvy-Stuart AL, Stirling HF, Kelnar CJ, Savage MO, Dunger DB, Buckler JM, Shalet SM

Clinical endocrinology1 May 1997Cited by 8 (Europe PMC)

PMID9231053 (opens in a new tab)DOI10.1046/j.1365-2265.1997.1790998.x (opens in a new tab)PepBankPUB-09231053
Publisher pagePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In children with radiation-induced GH deficiency, 1 year of GHRH(1-29)-NH2 increased height velocity from 3.3 to 6.0 cm/year.

    In plain wordsIn children with growth hormone deficiency after radiation, a year of GHRH(1-29)-NH2 raised growth speed from 3.3 to 6.0 cm a year.

    Peptide
    Sermorelin
    Outcome
    IncreaseHeight velocity
    Study

    n = 9

    Comparator
    Pretreatment values
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    15 micrograms/kg twice daily · subcutaneous · 1 yearAs given in this study (human).

    Measurements

    Height velocity
    3.3 cm/year
    before treatment
    Height velocity
    6 cm/year
    after 1 year of GHRH

    Source sentences

    Summary
    There was a significant increase in height velocity from 3.3 (SD 1.1) cm/year before treatment, to 6.0 (SDS 1.5) cm/year after 1 year of GHRH treatment (P = 0.004).
    2 context sentences
    Summary · context
    A multicentre study comparing growth before and after 1 year of treatment with GHRH (1-29)-NH2, 15 micrograms/kg twice daily, by subcutaneous injection in children with radiation-induced GH deficiency.
    Summary · context
    Nine children (six boys) with radiation-induced GH deficiency following cranial (n = 4) or craniospinal (n = 5) irradiation for a brain tumour distant from the hypothalamic-pituitary axis (n = 8) or prophylaxis against central nervous system leukaemia (n = 1) were studied.
  2. 02HumanNon-randomized trialEfficacy outcome

    Bone age increased by a mean of 1.1 years per chronological year during GHRH treatment in children with radiation-induced GH deficiency.

    In plain wordsIn children with growth hormone deficiency after radiation, bone age advanced by about 1.1 years for each year of GHRH treatment.

    Peptide
    Sermorelin
    Outcome
    IncreaseBone age advance
    Study

    n = 9

    Outcome group
    Bone and joint · Endocrine and hormones
    Studied dose
    15 micrograms/kg twice daily · subcutaneous · 1 yearAs given in this study (human).

    Measurements

    Bone age advance
    1.1 years/chronological year
    during GHRH treatment

    Source sentences

    Summary
    Bone age increased by a mean of 1.1 years/chronological year during treatment with GHRH.
    2 context sentences
    Summary · context
    A multicentre study comparing growth before and after 1 year of treatment with GHRH (1-29)-NH2, 15 micrograms/kg twice daily, by subcutaneous injection in children with radiation-induced GH deficiency.
    Summary · context
    Nine children (six boys) with radiation-induced GH deficiency following cranial (n = 4) or craniospinal (n = 5) irradiation for a brain tumour distant from the hypothalamic-pituitary axis (n = 8) or prophylaxis against central nervous system leukaemia (n = 1) were studied.
  3. 03HumanNon-randomized trialSafety outcome

    No adverse changes in biochemical or hormonal analyses were noted during GHRH(1-29)-NH2 treatment.

    In plain wordsIn children treated with GHRH(1-29)-NH2, blood chemistry and hormone tests showed no harmful changes.

    Peptide
    Sermorelin
    Outcome
    No significant changeBiochemical and hormonal safety
    Study

    n = 9

    Outcome group
    Adverse events · Whole body
    Studied dose
    15 micrograms/kg twice daily · subcutaneous · 1 yearAs given in this study (human).

    Source sentences

    Summary
    No adverse changes in biochemical or hormonal analyses were noted or adverse events that could be attributed to GHRH therapy.
    2 context sentences
    Summary · context
    A multicentre study comparing growth before and after 1 year of treatment with GHRH (1-29)-NH2, 15 micrograms/kg twice daily, by subcutaneous injection in children with radiation-induced GH deficiency.
    Summary · context
    Nine children (six boys) with radiation-induced GH deficiency following cranial (n = 4) or craniospinal (n = 5) irradiation for a brain tumour distant from the hypothalamic-pituitary axis (n = 8) or prophylaxis against central nervous system leukaemia (n = 1) were studied.
  4. 04HumanNon-randomized trialSafety outcome

    No adverse events that could be attributed to GHRH(1-29)-NH2 therapy were noted in children with radiation-induced GH deficiency.

    In plain wordsIn children treated with GHRH(1-29)-NH2, no side effects were linked to the treatment.

    Peptide
    Sermorelin
    Outcome
    No significant changeAdverse events attributable to GHRH
    Study

    n = 9

    Outcome group
    Adverse events · Whole body
    Studied dose
    15 micrograms/kg twice daily · subcutaneous · 1 yearAs given in this study (human).

    Source sentences

    Summary
    No adverse changes in biochemical or hormonal analyses were noted or adverse events that could be attributed to GHRH therapy.
    2 context sentences
    Summary · context
    A multicentre study comparing growth before and after 1 year of treatment with GHRH (1-29)-NH2, 15 micrograms/kg twice daily, by subcutaneous injection in children with radiation-induced GH deficiency.
    Summary · context
    Nine children (six boys) with radiation-induced GH deficiency following cranial (n = 4) or craniospinal (n = 5) irradiation for a brain tumour distant from the hypothalamic-pituitary axis (n = 8) or prophylaxis against central nervous system leukaemia (n = 1) were studied.
  5. 05HumanNon-randomized trialEfficacy outcome

    In cranially irradiated children, the growth velocity gain with GHRH was less than that seen in response to GH therapy.

    In plain wordsIn children after head radiation, GHRH raised growth speed, but less than growth hormone therapy did.

    Peptide
    Sermorelin
    Outcome
    DecreaseHeight velocity on GHRH versus GH therapy
    Study

    n = 9

    Comparator
    Growth hormone therapy
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    15 micrograms/kg twice daily · subcutaneous · 1 yearAs given in this study (human).

    Source sentences

    Summary
    GHRH was effective in increasing growth velocity but this was less than that seen in response to GH therapy
    3 context sentences
    Summary · context
    Subsequent height velocity during 1 year of GH therapy was 7.5 (SD 1.5)cm/year.
    Summary · context
    A multicentre study comparing growth before and after 1 year of treatment with GHRH (1-29)-NH2, 15 micrograms/kg twice daily, by subcutaneous injection in children with radiation-induced GH deficiency.
    Summary · context
    Nine children (six boys) with radiation-induced GH deficiency following cranial (n = 4) or craniospinal (n = 5) irradiation for a brain tumour distant from the hypothalamic-pituitary axis (n = 8) or prophylaxis against central nervous system leukaemia (n = 1) were studied.
  6. 06HumanNon-randomized trialEfficacy outcome

    In children who had craniospinal irradiation, GHRH maintained or improved leg length SDS.

    In plain wordsIn children who had radiation to brain and spine, GHRH kept or improved leg length scores.

    Peptide
    Sermorelin
    Outcome
    MixedLeg length SDS after craniospinal irradiation
    Study

    n = 5

    Comparator
    Pretreatment values
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    15 micrograms/kg twice daily · subcutaneous · 1 yearAs given in this study (human).

    Source sentences

    Summary
    GHRH maintained or improved the leg length SDS in children who had received craniospinal irradiation.
    2 context sentences
    Summary · context
    A multicentre study comparing growth before and after 1 year of treatment with GHRH (1-29)-NH2, 15 micrograms/kg twice daily, by subcutaneous injection in children with radiation-induced GH deficiency.
    Summary · context
    Nine children (six boys) with radiation-induced GH deficiency following cranial (n = 4) or craniospinal (n = 5) irradiation for a brain tumour distant from the hypothalamic-pituitary axis (n = 8) or prophylaxis against central nervous system leukaemia (n = 1) were studied.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    10 Oct 2026, 10:21 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:13 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.